Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the recipient of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 18,930,000 shares, an increase of 7.0% from the October 31st total of 17,690,000 shares. Based on an average trading volume of 747,500 shares, the short-interest ratio is currently 25.3 days.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of large investors have recently bought and sold shares of KPTI. GSA Capital Partners LLP grew its stake in shares of Karyopharm Therapeutics by 80.6% in the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock valued at $1,474,000 after buying an additional 792,283 shares during the period. Geode Capital Management LLC boosted its holdings in Karyopharm Therapeutics by 3.3% in the third quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock worth $1,125,000 after acquiring an additional 43,856 shares in the last quarter. AQR Capital Management LLC grew its stake in Karyopharm Therapeutics by 494.5% in the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock valued at $649,000 after acquiring an additional 622,194 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth about $494,000. Finally, FMR LLC grew its stake in shares of Karyopharm Therapeutics by 26.1% in the 3rd quarter. FMR LLC now owns 369,723 shares of the company’s stock worth $307,000 after acquiring an additional 76,510 shares in the last quarter. 66.44% of the stock is currently owned by institutional investors and hedge funds.

Karyopharm Therapeutics Stock Down 1.9 %

Shares of NASDAQ KPTI opened at $0.81 on Wednesday. The company has a market capitalization of $101.51 million, a PE ratio of -0.71 and a beta of 0.05. The firm has a fifty day simple moving average of $0.84 and a 200 day simple moving average of $0.87. Karyopharm Therapeutics has a twelve month low of $0.62 and a twelve month high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. The business had revenue of $38.78 million during the quarter, compared to analyst estimates of $37.86 million. During the same period in the prior year, the firm earned ($0.30) earnings per share. As a group, equities analysts expect that Karyopharm Therapeutics will post -0.94 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Karyopharm Therapeutics in a research report on Friday, November 1st. Royal Bank of Canada reiterated an “outperform” rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. StockNews.com cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Piper Sandler lifted their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Finally, Robert W. Baird dropped their price objective on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Karyopharm Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $5.00.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).